drugset / Trial / NCT02242305

Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort

NCT02242305

Phase 3 Completed 302 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

In contrast with Hyoscine Butylbromide Capsule 10mg, Study is to evaluate the efficacy and safety of Hyoscine Butylbromide tablets 10 mg (20mg, 3 times daily, orally) over a period of 3 days for the treatment of occasional or recurrent episodes of self-reported gastric or intestinal spasm-like pain or discomfort

Timeline

Start
2008-11-01
Primary completion
2009-07-20
Completion
2009-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Hyoscine butylbromide Unknown 10 mg Oral
Subject Hyoscine butylbromide Unknown 20 mg Oral

Indications

No indication recorded.